Reuters logo
10 months ago
BRIEF-Celgene Corp says data presented at ESMO 2016 adds to understanding of Abraxane as therapy for patients with historically challenging solid tumors
October 7, 2016 / 12:11 PM / 10 months ago

BRIEF-Celgene Corp says data presented at ESMO 2016 adds to understanding of Abraxane as therapy for patients with historically challenging solid tumors

1 Min Read

Oct 7 (Reuters) - Celgene Corp :

* New data being presented from abound trials demonstrate continued benefit of abraxane/carboplatin doublet therapy in NSCLC

* Data presented at ESMO 2016 adds to understanding of Abraxane as a therapy for patients with historically challenging solid tumors

* Latest edition of ESMO lung cancer guidelines have been updated to recommend use of abraxane + carboplatin in patients with stage iv NSCLC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below